Education
About Us
Working with TipRanks
Follow Us
Abcellera Biologics, Inc. (ABCL)
NASDAQ:ABCL
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 28.83M | $ 38.02M | $ 485.42M | $ 375.20M | $ 233.16M |
| Gross Profit | $ 28.83M | $ 38.02M | $ 418.99M | $ 329.69M | $ 206.01M |
| Operating Income | $ -314.77M | $ -237.21M | $ 216.51M | $ 204.41M | $ 156.03M |
| EBITDA | $ -204.15M | $ -192.16M | $ 260.17M | $ 239.15M | $ 169.62M |
| Net Income | $ -162.86M | $ -146.40M | $ 158.52M | $ 153.46M | $ 118.92M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 625.61M | $ 760.59M | $ 886.49M | $ 722.98M | $ 594.12M |
| Total Assets | $ 1.36B | $ 1.49B | $ 1.54B | $ 1.32B | $ 1.01B |
| Total Debt | $ 65.36M | $ 77.38M | $ 82.26M | $ 40.06M | $ 6.78M |
| Net Debt | $ -90.96M | $ -55.94M | $ -304.28M | $ -436.08M | $ -587.34M |
| Total Liabilities | $ 304.47M | $ 335.78M | $ 307.63M | $ 292.84M | $ 175.03M |
| Stockholders' Equity | $ 1.06B | $ 1.15B | $ 1.23B | $ 1.03B | $ 830.51M |
| Cash Flow | |||||
| Free Cash Flow | $ -186.95M | $ -121.38M | $ 204.70M | $ 186.13M | $ 8.02M |
| Operating Cash Flow | $ -108.56M | $ -43.88M | $ 277.36M | $ 244.58M | $ 22.69M |
| Investing Cash Flow | $ 121.41M | $ -221.11M | $ -352.63M | $ -332.25M | $ -119.78M |
| Financing Cash Flow | $ 12.77M | $ 10.36M | $ -1.63M | $ -3.89M | $ 683.65M |